# Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

Study · id `cardio:ct-nct03807921` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03807921](<https://clinicaltrials.gov/study/NCT03807921>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03807921

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT03807921. Randomized; single masking; primary purpose treatment. Start 2019-01-01 (actual); primary completion 2019-12-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT03807921, source copy `cardio:ctgov-nct03807921-2022-03-08`, retrieved 2026-10-26)
- Started: 2019-01-01 (actual) (ClinicalTrials.gov record NCT03807921, source copy `cardio:ctgov-nct03807921-2022-03-08`, retrieved 2026-10-26)
- Primary completion: 2019-12-30 (actual) (ClinicalTrials.gov record NCT03807921, source copy `cardio:ctgov-nct03807921-2022-03-08`, retrieved 2026-10-26)
- Completion: 2019-12-31 (actual) (ClinicalTrials.gov record NCT03807921, source copy `cardio:ctgov-nct03807921-2022-03-08`, retrieved 2026-10-26)
- Countries: Uruguay (ClinicalTrials.gov record NCT03807921, source copy `cardio:ctgov-nct03807921-2022-03-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03807921-2022-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
- Condition: Aortic Valve Stenosis
- Condition: Aortic Valve Disease
- Condition: Aortic Valve Insufficiency
- Condition: Aortic Valve Regurgitation
- Intervention (Drug): Warfarin
- Intervention (Drug): Aspirin
- Lead sponsor: Instituto Nacional de Cirugia Cardiaca, Uruguay
- Lead sponsor class: OTHER
- Collaborator: Universidad de la Republica
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic regurgitation (`cardio:aortic-regurgitation`)
- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)

## Provenance

Content hash: aaa4e0d74fca3ae275bd635ded7a6ed2b2503172d72f1e971cc9049805c21fa0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
